<DOC>
	<DOCNO>NCT00254878</DOCNO>
	<brief_summary>Currently two different brand modified-release formulation provide 50 % immediate release beads/pellets 50 % extended release beads/pellets , result rapid onset dual peak concentration plasma methylphenidate . One manufacture Novartis , one Medice ( Germany ) . The objective study test hypothesis Novartis product superior placebo clinically inferior formulation manufacture Medice .</brief_summary>
	<brief_title>Placebo-Controlled Comparison Two Different Brands Modified-Release Oral Dosage Forms Regarding Safety Efficacy Children With Attention Deficit Hyperactivity Disorder ( ADHD ) Aged 6 - 14</brief_title>
	<detailed_description>Currently two different brand modified-release formulation provide 50 % immediate release beads/pellets 50 % extended release beads/pellets , result rapid onset dual peak concentration plasma methylphenidate . One manufacture Novartis , one Medice ( Germany ) . The objective study test hypothesis Novartis product superior placebo clinically inferior formulation manufacture Medice .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Patients meet follow inclusion criterion eligible enrollment study : Male female patient age 614 . Patients diagnosis ADHD type accord DSMIV criterion , establish history , psychiatric examination structure diagnostic interview ( KiddieSadsPresent Lifetime Version ) Patients , whose symptom adequately control stable welltolerated dose immediate release methylphenidate equivalent 20mg one month screening . Patients comorbid psychiatric condition symptoms require current pharmacological treatment ( e.g . major depression , psychosis ) . Patients take concomitant medication likely interfere study drug confound efficacy safety assessment , e.g . Tricyclic antidepressant , buproprion , clonidine , buspirone 2 week randomization . Atomoxetine 2 week randomization . Fluoxetine antipsychotic 1 month randomization . Pemoline amphetamines 1 week randomization . Patients know nonresponse methylphenidate . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>ADHD , Methylphenidate hydrochloride , modified-release</keyword>
</DOC>